ES2934698T3 - Vacunas contra el virus de la hepatitis B - Google Patents
Vacunas contra el virus de la hepatitis B Download PDFInfo
- Publication number
- ES2934698T3 ES2934698T3 ES16791573T ES16791573T ES2934698T3 ES 2934698 T3 ES2934698 T3 ES 2934698T3 ES 16791573 T ES16791573 T ES 16791573T ES 16791573 T ES16791573 T ES 16791573T ES 2934698 T3 ES2934698 T3 ES 2934698T3
- Authority
- ES
- Spain
- Prior art keywords
- hbv
- arenavirus
- protein
- infectious
- hbc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250639P | 2015-11-04 | 2015-11-04 | |
| PCT/EP2016/076591 WO2017076988A1 (en) | 2015-11-04 | 2016-11-03 | Vaccines against hepatitis b virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2934698T3 true ES2934698T3 (es) | 2023-02-24 |
Family
ID=57249796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16791573T Active ES2934698T3 (es) | 2015-11-04 | 2016-11-03 | Vacunas contra el virus de la hepatitis B |
Country Status (20)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2604695T (lt) | 2007-12-27 | 2022-12-12 | Universität Zürich | Replikacijos defektų turintys arenaviruso vektoriai |
| JP6818551B2 (ja) | 2013-12-03 | 2021-01-20 | ホオキパ バイオテック ジーエムビーエイチ | Ｃｍｖワクチン |
| CA2967720C (en) * | 2014-11-13 | 2024-01-02 | Universite De Geneve | Tri-segmented arenaviruses as vaccine vectors |
| AU2016274655B2 (en) | 2015-06-10 | 2021-06-17 | Hookipa Biotech Gmbh | HPV vaccines |
| SG11201803474UA (en) * | 2015-11-04 | 2018-05-30 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| CN108697775B (zh) | 2015-11-12 | 2023-05-09 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的沙粒病毒颗粒 |
| PE20191353A1 (es) | 2016-10-14 | 2019-10-01 | Prec Biosciences Inc | Meganucleasas disenadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b |
| JP2022010187A (ja) * | 2017-02-03 | 2022-01-14 | 株式会社三洋物産 | 遊技機 |
| JP2022010188A (ja) * | 2017-02-03 | 2022-01-14 | 株式会社三洋物産 | 遊技機 |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3986455A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof |
| WO2020255011A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
| UA129329C2 (uk) | 2019-06-25 | 2025-03-19 | Гіліад Сайєнсіз, Інк. | ЗЛИТІ БІЛКИ FLT3L-Fc |
| MX2022003658A (es) | 2019-09-30 | 2022-04-25 | Gilead Sciences Inc | Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb. |
| AU2020377504A1 (en) * | 2019-11-07 | 2022-06-02 | Universität Basel | Arenaviruses as vectors |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| AU2020412875A1 (en) | 2019-12-24 | 2022-06-23 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| KR102375703B1 (ko) | 2020-07-28 | 2022-03-17 | 경북대학교 산학협력단 | 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템 |
| AU2022244100A1 (en) | 2021-03-23 | 2023-10-19 | Hookipa Biotech Gmbh | Arenaviruses used in treatments of prostate cancer |
| US20250034213A1 (en) * | 2021-04-21 | 2025-01-30 | La Jolla Institute For Immunology | Engineered arenavirus glycoprotein compositions, methods and use thereof |
| CN113201051B (zh) * | 2021-04-27 | 2022-08-02 | 复旦大学 | 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用 |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| KR20240023628A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2025056782A1 (en) | 2023-09-15 | 2025-03-20 | Hookipa Biotech Gmbh | Arenavirus formulations, methods and uses thereof |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| JPH1084967A (ja) * | 1996-09-19 | 1998-04-07 | Fujirebio Inc | Ｂ型肝炎のｅ抗原 |
| WO2000032625A1 (en) * | 1998-12-04 | 2000-06-08 | Biogen, Inc. | Hbv core antigen particles with multiple immunogenic components attached via peptide ligands |
| FR2803599B1 (fr) * | 2000-01-06 | 2004-11-19 | Inst Nat Sante Rech Med | Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications |
| US20100183652A1 (en) * | 2002-02-21 | 2010-07-22 | Mark Page | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS |
| EP1888622A1 (en) * | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions for inducing an immune response against hepatitis b |
| CN101037476A (zh) * | 2006-03-15 | 2007-09-19 | 复旦大学 | 一种用于制备抗体化乙肝疫苗的融合蛋白及其载体 |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP2133365B1 (en) * | 2006-12-27 | 2017-05-17 | Emory University | Compositions and methods for the treatment of infections and tumors |
| LT2604695T (lt) | 2007-12-27 | 2022-12-12 | Universität Zürich | Replikacijos defektų turintys arenaviruso vektoriai |
| US10076570B2 (en) * | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
| US9393299B2 (en) | 2009-08-07 | 2016-07-19 | Transgene S.A. | Composition for treating HBV infection |
| CN103476426B (zh) * | 2011-02-12 | 2021-08-10 | 全球免疫股份有限公司 | 用于慢性乙型肝炎病毒感染的基于酵母的治疗剂 |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| JP6219849B2 (ja) | 2012-01-24 | 2017-10-25 | サンフォード ヘルス | 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド |
| WO2014140301A1 (en) | 2013-03-15 | 2014-09-18 | Université De Genève | Anti-mycobacterial vaccines |
| GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
| JP6818551B2 (ja) | 2013-12-03 | 2021-01-20 | ホオキパ バイオテック ジーエムビーエイチ | Ｃｍｖワクチン |
| WO2015183895A1 (en) | 2014-05-27 | 2015-12-03 | University Of Rochester | Novel arenavirus vaccine |
| US9943585B2 (en) | 2014-07-30 | 2018-04-17 | University Of Rochester | Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) |
| ES2746150T3 (es) | 2014-09-22 | 2020-03-04 | Univ Minnesota | Sistema de genética inversa para el virus Pichindé y métodos de uso |
| GB201419572D0 (en) | 2014-11-03 | 2014-12-17 | Pirbright Inst The | Virus |
| CA2967720C (en) | 2014-11-13 | 2024-01-02 | Universite De Geneve | Tri-segmented arenaviruses as vaccine vectors |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| AU2016274655B2 (en) | 2015-06-10 | 2021-06-17 | Hookipa Biotech Gmbh | HPV vaccines |
| ES3021881T3 (en) | 2015-10-23 | 2025-05-27 | Pasteur Institut | Recombinant mopeia virus and vaccine platform |
| SG11201803474UA (en) * | 2015-11-04 | 2018-05-30 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| CN108697775B (zh) | 2015-11-12 | 2023-05-09 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的沙粒病毒颗粒 |
| US10980877B2 (en) | 2016-04-28 | 2021-04-20 | The University Of Chicago | Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen |
| CA3023599A1 (en) | 2016-05-18 | 2017-11-23 | Hookipa Biotech Gmbh | Tri-segmented pichinde viruses as vaccine vectors |
| CA3039356A1 (en) | 2016-11-04 | 2018-05-11 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| WO2018185307A1 (en) | 2017-04-07 | 2018-10-11 | Hookipa Biotech Ag | Arenavirus particles to treat solid tumors |
-
2016
- 2016-11-03 SG SG11201803474UA patent/SG11201803474UA/en unknown
- 2016-11-03 EP EP22201924.2A patent/EP4177348A1/en active Pending
- 2016-11-03 IL IL259077A patent/IL259077B2/en unknown
- 2016-11-03 EP EP16791573.5A patent/EP3371316B1/en active Active
- 2016-11-03 CN CN201680077751.0A patent/CN108779472B/zh active Active
- 2016-11-03 FI FIEP16791573.5T patent/FI3371316T3/fi active
- 2016-11-03 AU AU2016348675A patent/AU2016348675B2/en active Active
- 2016-11-03 KR KR1020187015548A patent/KR102832178B1/ko active Active
- 2016-11-03 SI SI201631654T patent/SI3371316T1/sl unknown
- 2016-11-03 PL PL16791573.5T patent/PL3371316T3/pl unknown
- 2016-11-03 IL IL314371A patent/IL314371A/en unknown
- 2016-11-03 KR KR1020257022585A patent/KR20250107977A/ko active Pending
- 2016-11-03 LT LTEPPCT/EP2016/076591T patent/LT3371316T/lt unknown
- 2016-11-03 PT PT167915735T patent/PT3371316T/pt unknown
- 2016-11-03 US US15/773,512 patent/US11214598B2/en active Active
- 2016-11-03 ES ES16791573T patent/ES2934698T3/es active Active
- 2016-11-03 JP JP2018541546A patent/JP6914950B2/ja active Active
- 2016-11-03 HU HUE16791573A patent/HUE060648T2/hu unknown
- 2016-11-03 CA CA3003557A patent/CA3003557A1/en active Pending
- 2016-11-03 WO PCT/EP2016/076591 patent/WO2017076988A1/en not_active Ceased
- 2016-11-03 DK DK16791573.5T patent/DK3371316T3/da active
- 2016-11-03 HR HRP20221474TT patent/HRP20221474T1/hr unknown
- 2016-11-03 CN CN202211051785.6A patent/CN115948467A/zh active Pending
- 2016-11-03 MX MX2018005569A patent/MX2018005569A/es unknown
-
2018
- 2018-05-03 MX MX2023013140A patent/MX2023013140A/es unknown
-
2021
- 2021-07-14 JP JP2021116562A patent/JP2021182922A/ja active Pending
- 2021-11-24 US US17/535,121 patent/US20220073568A1/en not_active Abandoned
-
2023
- 2023-01-10 AU AU2023200108A patent/AU2023200108B2/en active Active
- 2023-10-19 JP JP2023180121A patent/JP7777907B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2934698T3 (es) | Vacunas contra el virus de la hepatitis B | |
| ES2834698T3 (es) | Medios y métodos para tratar el HBV | |
| JP7254018B2 (ja) | ワクチンベクターとしての三セグメントピチンデウイルス | |
| CN105980570B (zh) | Cmv疫苗 | |
| ES2671381T3 (es) | Composiciones inmunoterapéuticas para el tratamiento o prevención de infección por virus de hepatitis delta | |
| TW201734208A (zh) | Ｈｂｖ聚合酶突變體 | |
| BR112012002628B1 (pt) | Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes | |
| JP2017535267A (ja) | ワクチンベクターとしての３分節型アレナウイルス | |
| HK40093198A (en) | Vaccines against hepatitis b virus | |
| HK40090610A (zh) | 针对乙型肝炎病毒的疫苗 | |
| HK1255847B (en) | Vaccines against hepatitis b virus | |
| BR122024003112A2 (pt) | Vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, uso de vetor viral, ácido nucleico isolado | |
| BR122024003112B1 (pt) | Vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, uso de vetor viral, ácido nucleico isolado | |
| BR112018009032B1 (pt) | Vetor viral de arenavírus infeccioso, composição farmacêutica ou imunogênica ou vacina, uso de um vetor viral, ácido nucleico isolado e uso do ácido nucléico | |
| NZ741950B2 (en) | Vaccines against hepatitis b virus | |
| HK1263252B (en) | Vaccines against hepatitis b virus | |
| HK1263252A1 (en) | Vaccines against hepatitis b virus | |
| HK40063367A (en) | Cmv vaccines | |
| BR112018013387B1 (pt) | Vetor de vacinação recombinante, usos de um vetor de vacinação recombinante, vacina ou composição farmacêutica e kit |